Navigation Links
Regenicin Completes Acquisition of Worldwide Exclusive Know-How Technology License from Lonza Walkersville
Date:8/18/2010

NEW YORK, Aug. 18 /PRNewswire-FirstCall/ -- Regenicin, Inc. (OTC Bulletin Board: WDSTD), a development stage biotechnology company, announced today that it has completed an initial $3.25 million funding in conjunction with its acquisition of a worldwide exclusive license to know-how technology controlled by Lonza Walkersville ("Lonza Agreement").  Lonza Walkersville is a subsidiary of Lonza Group Ltd. (SIX: LONN), one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries and the largest cell therapy manufacturer in the world.

The Lonza Agreement provides Regenicin with the worldwide marketing rights to a proprietary tissue-engineered skin substitute technology intended to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds and a variety of plastic surgery procedures.  Regenicin's management team intends to use its expertise, with the assistance of Lonza Walkersville, to further enhance its capabilities and seek approval by the U.S. Food and Drug Administration for commercial sale. Regenicin plans to seek marketing approval for this revolutionary product throughout the world under the brand name PermaDerm™.  

Pursuant to the Lonza Agreement, Lonza will retain exclusive manufacturing rights for PermaDerm™ products.  Additionally, a license to the patent rights and related key intellectual property comprising the technology, developed at the University of California, University of Colorado, the University of Cincinnati and Shriners Hospitals for Children, may be acquired by Regenicin if FDA approval is obtained.

Regenicin secured the initial financing through a combination of convertible loans and a private placement of its common stock with several major institutions and accredited investors. NewOak Capital, Inc. and Smith Point, Ltd. acted as co-placement agents.  

"We are excited to have secured the funds necessary to help us complete this licensing agreement with Lonza and to prepare to advance this important technology to commercialization.  We believe Regenicin is now poised to address a significant unmet medical need as PermaDerm™ is the only tissue-engineered skin prepared from a patient's own skin cells," Randall McCoy, Chief Executive Officer of Regenicin said.  "The technology combines cultured epithelium with a collagen-fibroblast implant that produces a skin substitute that contains both epidermal and dermal components.  This model has been shown in preclinical studies to generate a functional skin barrier, which is an important step towards realizing the potential of regenerative medicine."

About Regenicin, Inc.

Regenicin, Inc. is a development stage company focusing on next-generation tissue-engineered skin substitutes to restore the qualities of healthy human skin. Regenicin is a publicly traded company, with headquarters in Little Falls, NJ. Additional information can be found in the company's filings with the Securities and Exchange Commission located at www.sec.gov.


'/>"/>
SOURCE Regenicin, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. DATATRAK Completes Sale of 357,857 Common Shares to Directors and Management
2. Resverlogix Completes Dosing for ASSERT Trial
3. Xybion Completes Acquisition of Stelex and Vital-Path, Leaders in Business Process Software and Consulting Services for Regulated Industries, from GE Healthcare
4. Nile Therapeutics Completes Dose Escalation in Ongoing Phase II Study
5. Hendrick Construction Completes Oak Ridge National Laboratory Expansion
6. Oncolytics Biotech(R) Inc. Completes Patient Enrollment in Phase I Portion of U.S. Phase I/II Recurrent Malignant Gliomas Clinical Trial
7. Therapeutic Proteins Inc. Completes First Independent, Dedicated Biosimilars Manufacturing Facility in U.S.
8. NOVAVAX Completes Enrollment of Pivotal H1N1 Influenza Vaccine Clinical Trial in Mexico
9. EUSA Pharma Completes Establishment of Commercial Infrastructure With Appointment of President for Europe and International Region
10. APT Pharmaceuticals Completes Enrollment in Phase III for Inhaled Cyclosporine
11. Ocera Therapeutics Completes Phase 2B Enrollment in the ASTUTE Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2017)... ... October 06, 2017 , ... ... providing advanced instruments and applications consulting for microscopy and surface analysis, Nanoscience ... application consulting, Nanoscience Analytical offers a broad range of contract analysis services ...
(Date:10/7/2017)...  The 2017 Nobel Prize in Chemistry recognizes ... Joachim Frank and Richard Henderson ... (cryo-EM) have helped to broaden the use ... The winners worked with systems manufactured by Thermo ... resolved, three-dimensional images of protein structures that lead ...
(Date:10/6/2017)... Washington, D.C. (PRWEB) , ... October 06, 2017 ... ... Cure) will host a lunch discussion and webinar on INSIGhT, the first-ever adaptive ... INSIGhT Principal Investigator, Dana-Farber Cancer Institute. The event is free and open to ...
(Date:10/5/2017)... ... 2017 , ... Understanding the microbiome, the millions of bacteria that live in ... Are My Future, the newest exhibit on display at the University City Science Center’s ... through the lens of the gut microbiome. , Gut Love opens October 12, ...
Breaking Biology Technology:
(Date:6/23/2017)... ITHACA, N.Y. , June 23, 2017  IBM ... in dairy research, today announced a new collaboration using ... the chances that the global milk supply is impacted ... project, Cornell University has become the newest academic institution ... Chain, a food safety initiative that includes IBM Research, ...
(Date:5/6/2017)... , May 5, 2017 ... just announced a new breakthrough in biometric authentication ... exploits quantum mechanical properties to perform biometric authentication. These ... smart semiconductor material created by Ram Group and ... finance, entertainment, transportation, supply chains and security. Ram ...
(Date:4/13/2017)... April 13, 2017 UBM,s Advanced Design and ... will feature emerging and evolving technology through its 3D ... will run alongside the expo portion of the event ... and demonstrations focused on trending topics within 3D printing ... and manufacturing event will take place June 13-15, 2017 at ...
Breaking Biology News(10 mins):